Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00724984 · FLOW

Participant flow

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma · Source last updated 2014-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. id
    FG000
    title
    Cohort 1(30mg/m2,5days/wk)/Phase 1
  2. id
    FG001
    title
    Cohort 2(45mg/m2,5days/wk)/Phase 1
  3. id
    FG002
    title
    Cohort 3(45mg/m2,7days/wk)/Phase 1
  4. id
    FG003
    title
    Cohort 4(60mg/m2,7days/wk)/Phase 1
  5. id
    FG004
    title
    Follicular/Phase II
  6. id
    FG005
    title
    Mantle Cell Lymphoma/Phase II
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        5
      2. group Id
        FG001
        num Subjects
        8
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        9
      5. group Id
        FG004
        num Subjects
        16
      6. group Id
        FG005
        num Subjects
        14
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        7
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        7
      5. group Id
        FG004
        num Subjects
        12
      6. group Id
        FG005
        num Subjects
        9
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        2
      5. group Id
        FG004
        num Subjects
        4
      6. group Id
        FG005
        num Subjects
        5
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. id
    FG000
    title
    Cohort 1(30mg/m2,5days/wk)/Phase 1
  2. id
    FG001
    title
    Cohort 2(45mg/m2,5days/wk)/Phase 1
  3. id
    FG002
    title
    Cohort 3(45mg/m2,7days/wk)/Phase 1
  4. id
    FG003
    title
    Cohort 4(60mg/m2,7days/wk)/Phase 1
  5. id
    FG004
    title
    Follicular/Phase II
  6. id
    FG005
    title
    Mantle Cell Lymphoma/Phase II
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        5
      2. group Id
        FG001
        num Subjects
        8
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        9
      5. group Id
        FG004
        num Subjects
        16
      6. group Id
        FG005
        num Subjects
        14
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        7
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        7
      5. group Id
        FG004
        num Subjects
        12
      6. group Id
        FG005
        num Subjects
        9
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        2
      5. group Id
        FG004
        num Subjects
        4
      6. group Id
        FG005
        num Subjects
        5
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice